Patents by Inventor Yawei Ni

Yawei Ni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230330205
    Abstract: A dry powder Norovirus vaccine is provided, which comprises at least two Norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against Norovirus infections.
    Type: Application
    Filed: February 2, 2023
    Publication date: October 19, 2023
    Inventors: Ron COBB, Michael SPRINGER, Yawei NI
  • Patent number: 11596680
    Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: March 7, 2023
    Assignee: RESILIENCE GOVERNMENT SERVICES, INC.
    Inventors: Ron Cobb, Michael Springer, Yawei Ni
  • Patent number: 11219682
    Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: January 11, 2022
    Assignee: KJ Biosciences LLC
    Inventor: Yawei Ni
  • Patent number: 10912825
    Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: February 9, 2021
    Assignee: KJ Biosciences LLC
    Inventors: Yawei Ni, Jianhua Guo
  • Publication number: 20200345828
    Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.
    Type: Application
    Filed: May 18, 2020
    Publication date: November 5, 2020
    Inventors: RON COBB, MICHAEL SPRINGER, YAWEI NI
  • Publication number: 20190142930
    Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 16, 2019
    Inventors: Yawei Ni, Jianhua Guo
  • Publication number: 20180333478
    Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
    Type: Application
    Filed: February 9, 2018
    Publication date: November 22, 2018
    Inventor: Yawei Ni
  • Publication number: 20180243397
    Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.
    Type: Application
    Filed: August 26, 2016
    Publication date: August 30, 2018
    Inventors: RON COBB, MICHAEL SPRINGER, YAWEI NI
  • Publication number: 20180147424
    Abstract: A nasal air filter comprises two hollow nostril adapters, a body, and a filter element. The body is panel shaped to conform to the bottom of the nose. The two hollow nostril adapters for insertion into nostrils at one end and attached side-by-side at the other end to one side of the body via corresponding thru holes on the body. The filter element is secured to the opposite side of the body, creating an open space between the bottom surface of the body and filter element to allow airflow through both nostril adapters and the entire surface area of the filter element. The filter element fitting within the raised edge of the body has a surface area larger than the combined area of the orifices of both nostrils, allowing efficient air filtering and ease of breathing. The device may comprise a nose cover connected around the top edge of the body shaped to conform to the top of the nose.
    Type: Application
    Filed: April 23, 2016
    Publication date: May 31, 2018
    Applicant: KJ Biosciences LLC
    Inventor: Yawei Ni
  • Patent number: 9889190
    Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: February 13, 2018
    Assignee: KJ Biosciences LLC
    Inventor: Yawei Ni
  • Publication number: 20160095917
    Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Inventor: Yawei Ni
  • Patent number: 9241986
    Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA-binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: January 26, 2016
    Assignee: KJ BIOSCIENCES LLC
    Inventor: Yawei Ni
  • Publication number: 20150098966
    Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
    Type: Application
    Filed: May 14, 2013
    Publication date: April 9, 2015
    Applicant: KJ Biosciences LLC
    Inventors: Yawei Ni, Jianhua Guo
  • Publication number: 20130171181
    Abstract: Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA-binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.
    Type: Application
    Filed: December 22, 2010
    Publication date: July 4, 2013
    Applicant: KJ BIOSCIENCES LLC
    Inventor: Yawei Ni
  • Patent number: 7705135
    Abstract: Pectins having a combination of unexpectedly high molecular weights and low degrees of methylation have been isolated from Aloe vera plants, are superior gel pectins for forming calcium cross-lined gels. Such pectins can be obtained by extracting homogenized Aloe Vera plants or portions thereof. These pectins can be used to prepare pharmaceutical compositions comprising pharmacological agents for application to animals and humans, so as to provide controlled release of the pharmacological agent.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: April 27, 2010
    Assignee: Nanotherapeutics, Inc.
    Inventors: Yawei Ni, Kenneth M. Yates, Ryszard Zarzycki
  • Patent number: 7691986
    Abstract: Pectins having a combination of unexpectedly high molecular weights and low degrees of methylation have been isolated. These high molecular weight, low degree of methylation pectins form gels at unexpectedly low concentrations. Such pectins can be obtained by extracting homogenized Aloe Vera plants or portions thereof. These pectins can be used to prepare pharmaceutical compositions comprising pharmacological agents encapsulated in a pectin gel, for application to animals and humans so as to provide controlled release of the pharmacological agent.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: April 6, 2010
    Assignee: Nanotherapeutics, Inc.
    Inventors: Yawei Ni, Kenneth M. Yates, Ryszard Zarzycki
  • Patent number: 7494669
    Abstract: In-situ gelation of a pectic substance. Composition, method of preparation, and method of use of a pectin in-situ gelling formulation for the delivery and sustained release of a physiologically active agent to the body of an animal. The pectin can be isolated from Aloe vera.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: February 24, 2009
    Assignee: Carrington Laboratories, Inc.
    Inventors: Yawei Ni, Kenneth M. Yates
  • Publication number: 20080026446
    Abstract: A composition combining an extracellular matrix-degrading protease and a growth factor related to epithelial cell functions together without inactivation or degradation of the growth factor by the protease. Preferably, the protease is plasmin/plasminogen or a related one, and the growth factor is KGF or a related one. The combination associates two independent, but synergistic functions essential to the re-epithelialization process or healing process, i.e, stimulating epithelial cell proliferation/differentiation and facilitating its migration by clearing the extracellular matrix components. The combination may be constructed in various ways and can be used to treat wounds or any other disease conditions involving cells of epithelial origin or any other cell types that the growth factor may affect.
    Type: Application
    Filed: March 2, 2007
    Publication date: January 31, 2008
    Applicant: Carrington Laboratories, Inc.
    Inventors: Yawei Ni, Konnoth Yates
  • Patent number: 7202066
    Abstract: A composition combining an extracellular matrix-degrading protease and a growth factor related to epithelial cell functions together without inactivation or degradation of the growth factor by the protease. Preferably, the protease is plasmin/plasminogen or a related one, and the growth factor is KGF or a related one. The combination associates two independent, but synergistic functions essential to the re-epithelialization process or healing process, i.e, stimulating epithelial cell proliferation/differentiation and facilitating its migration by clearing the extracellular matrix components. The combination may be constructed in various ways and can be used to treat wounds or any other disease conditions involving cells of epithelial origin or any other cell types that the growth factor may affect.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: April 10, 2007
    Assignee: Carrington Laboratories, Inc.
    Inventors: Yawei Ni, Kenneth M. Yates
  • Publication number: 20060211653
    Abstract: Pectins having a combination of unexpectedly high molecular weights and low degrees of methylation have been isolated from Aloe vera plants, are superior gel pectins for forming calcium cross-lined gels. Such pectins can be obtained by extracting homogenized Aloe Vera plants or portions thereof. These pectins can be used to prepare pharmaceutical compositions comprising pharmacological agents for application to animals and humans, so as to provide controlled release of the pharmacological agent.
    Type: Application
    Filed: May 19, 2006
    Publication date: September 21, 2006
    Inventors: Yawei Ni, Kenneth Yates, Ryszard Zarzycki